Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | LIPE | Q05469 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525767 | 0.88 | LIPE (0.43) | AAK1CA1CA2CA9LIPE | |
| SCHEMBL6532891 | 0.84 | CA1 (0.44) | AAK1CA1CA2CA9LIPE | |
| SCHEMBL1646602 | 0.82 | AAK1 (0.52) | AAK1CA1CA2CA9PRMT5 | |
| SCHEMBL14560 | 0.80 | LIPE (0.48) | AAK1LIPEPRMT5WDR77 | |
| SCHEMBL1255934 | 0.80 | AAK1 (0.54) | AAK1CA1CA2CA9NAMPT | |
| SCHEMBL2829176 | 0.79 | POLB (0.56) | NAMPTF10HDAC1MEN1KMT2A | |
| SCHEMBL25422411 | 0.79 | NPC1 (0.59) | CA1CA2CA9NAMPTMEN1 | |
| SCHEMBL25984541 | 0.79 | RAB9A (0.56) | CA1CA2CA9LIPEHDAC1 | |
| SCHEMBL3770952 | 0.79 | CA1 (0.43) | AAK1CA1CA2CA9NAMPT | |
| SCHEMBL1990625 | 0.79 | CA1 (0.54) | AAK1CA1CA2CA9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735429-B2 | Benzamide compounds useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| EP-1954690-B1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-06 | — | — | US | disclosed |
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-03-25 | — | — | US | disclosed |
| EP-1828153-A1 | N-(2-AMINOPHENYL)-4-(5-((ETHYLAMINO)METHYL)-1,3-THIAZOL-2-YL)BENZAMIDE AND N-(2-AMINOPHENYL)-4-(5-((ISOPROPYLAMINO)METHYL)-1,3-THIAZOL-2-YL)BENZAMIDE AS HDAC INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007071961-A1 | BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007045844-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006075160-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006064246-A1 | N- (2-AMINOPHENYL) -4- (5- ((ETHYLAMINO) METHYL) 1,3-THIAZOL-2-YL) BENZAMIDE AND N- (2-AMINOPHEYNL) -4- (5- ((ISOPROPYLAMINO) METHYL) -1,3-THIAZOL-2-YL) BENZAMIDE AS HDAC INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| EP-1495002-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astrazeneca AB (SE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | AAK1 2873/4885CA1 1233/4885CA2 769/4885 |
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | HDAC1, HDAC2, HDAC3 | AAK1 3861/4885CA1 3450/4885CA2 2046/4885 |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | HDAC3, HDAC1, HDAC4 | AAK1 3210/4885CA1 2280/4885CA2 855/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | AAK1 3270/4885CA1 2249/4885CA2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.